Ozenoxacin: A novel topical antibiotic

Santhosh, Parvathy; Thomas, M.

doi:10.25259/ijdvl_191_20

Cited by 3 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is clearly a need for newer antimicrobials having different mode of action and also showing good effect against resistant and non-responding strains in the management of impetigo. 19…”

Section: Antimicrobial Resistancementioning

confidence: 99%

Ozenoxacin: A novel topical quinolone

Shirsat¹,

Shah²,

Trailokya³

2022

IJCED

View full text Add to dashboard Cite

The burden of dermatological conditions is huge on the global health accounting for 44.1 million DALYs worldwide. Impetigo is a highly contagious bacterial infection with 2.5 time’s greater likelihood in pediatrics (12.3%) than in adults (4.9%). Micro-organisms causing impetigo include bacteria like or both. The management of Impetigo is with topical and systemic antimicrobial agents. Topical antimicrobial resistance is on the rise in patients with Impetigo. Therefore, there is clearly a need for newer antimicrobials having different mode of action and showing good activity against non-responding strains in the management of impetigo. Ozenoxacin is a novel, topical quinolone with a good safety and tolerability profile in the management of Impetigo. The authorizing bodies namely USFDA, European Medical Agency, and DCGI have approved the use of Ozenoxacin 1% cream for the topical treatment of impetigo due to in adult and pediatric patients 2 months of age and older.

show abstract

Section: Antimicrobial Resistancementioning

confidence: 99%

Ozenoxacin: A novel topical quinolone

Shirsat¹,

Shah²,

Trailokya³

2022

IJCED

View full text Add to dashboard Cite

show abstract

“…As a result, it shows an increased efficacy against fluoroquinolone-resistant bacteria. Ozenoxacin is currently available on the US and Canadian market as a 1% cream for topical use [ 23 , 43 ]. The same mechanism of action is shared by delafloxacin (Fig.…”

Section: Examples Of Mtdls Introduced Before 2022mentioning

confidence: 99%

Polypharmacology: promises and new drugs in 2022

Ryszkiewicz,

Malinowska,

Schlicker

2023

Pharmacol. Rep

View full text Add to dashboard Cite

Polypharmacology is an emerging strategy of design, synthesis, and clinical implementation of pharmaceutical agents that act on multiple targets simultaneously. It should not be mixed up with polytherapy, which is based on the use of multiple selective drugs and is considered a cornerstone of current clinical practice. However, this ‘classic’ approach, when facing urgent medical challenges, such as multifactorial diseases, increasing resistance to pharmacotherapy, and multimorbidity, seems to be insufficient. The ‘novel’ polypharmacology concept leads to a more predictable pharmacokinetic profile of multi-target-directed ligands (MTDLs), giving a chance to avoid drug-drug interactions and improve patient compliance due to the simplification of dosing regimens. Plenty of recently marketed drugs interact with multiple biological targets or disease pathways. Many offer a significant additional benefit compared to the standard treatment regimens. In this paper, we will briefly outline the genesis of polypharmacology and its differences to polytherapy. We will also present leading concepts for obtaining MTDLs. Subsequently, we will describe some successfully marketed drugs, the mechanisms of action of which are based on the interaction with multiple targets. To get an idea, of whether MTDLs are indeed important in contemporary pharmacology, we also carefully analyzed drugs approved in 2022 in Germany: 10 out of them were found multi-targeting, including 7 antitumor agents, 1 antidepressant, 1 hypnotic, and 1 drug indicated for eye disease.

show abstract

“…These studies can also aid in determining the drug substance's re‐test period or the drug product's shelf life. Ozenoxacin (OXC) is an antibiotic of the quinolone class and is administered topically to treat a bacterial skin infection known as impetigo 2,3 . In December 2017, the U.S. Food and Drug Administration approved OXC as a 1% topical cream for the treatment of impetigo caused by Streptococcus pyogenes or Staphylococcus aureus in adults and children over 2 months 4 .…”

Section: Introductionmentioning

confidence: 99%

“…Ozenoxacin (OXC) is an antibiotic of the quinolone class and is administered topically to treat a bacterial skin infection known as impetigo. 2,3 In December 2017, the U.S. Food and Drug Administration approved OXC as a 1% topical cream for the treatment of impetigo caused by Streptococcus pyogenes or Staphylococcus aureus in adults and children over 2 months. 4 OXC exerts its antibacterial effect by blocking the activity of DNA gyrase A and topoisomerase IV enzymes, which play a crucial role in bacterial DNA replication and transcription.…”

mentioning

confidence: 99%

Identification, characterisation and in silico ADMET prediction of ozenoxacin and its degradation products using high‐performance liquid chromatography‐photodiode array and liquid chromatography‐quadrupole time‐of‐flight‐tandem mass spectrometry

Matta,

Sundararajan

2023

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

RationaleOzenoxacin (OXC) is an antibiotic used topically to treat impetigo. This study aimed to evaluate the degradation products (DP) of OXC drug substance under different stress conditions, including hydrolysis, oxidation, thermal and photolysis, in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines Q1A(R2) and Q1B. The analytical technique was validated in compliance with ICH Q2(R1) requirements.MethodsThe drug substance underwent degradation under various forced degradation conditions, including thermal, oxidative, photolytic and hydrolytic (neutral, acidic and basic) degradation. Overall, four DPs were formed under oxidative stress conditions with AIBN. The formed DPs were identified and separated using a Shimadzu LC system with a reversed‐phase Phenomenex Kinetex C18 column (4.6 × 250 mm, 5 μm), using 10 mM NH4CH3COOH buffer (pH −5.0) as mobile phase A and acetonitrile as mobile phase B at a detection wavelength of 254 nm.Results and ConclusionThe drug was found to be stable in neutral, acidic, basic and oxidative degradation conditions with hydrogen peroxide. Liquid chromatography‐electrospray ionisation‐quadrupole time‐of‐flight‐tandem mass spectrometry‐ was employed in positive ionisation mode to analyse both the drug and the mass of the identified DP. The mechanism and the pathway of mass fragmentation have been proposed. The developed method was accurate, repeatable, linear and selective for further research. The ADMET Predictor software was applied to predict the in silico toxicity of the drugs and its DPs as well as their physicochemical characteristics.

show abstract

Ozenoxacin: A novel topical antibiotic

Cited by 3 publications

References 26 publications

Ozenoxacin: A novel topical quinolone

Ozenoxacin: A novel topical quinolone

Polypharmacology: promises and new drugs in 2022

Identification, characterisation and in silico ADMET prediction of ozenoxacin and its degradation products using high‐performance liquid chromatography‐photodiode array and liquid chromatography‐quadrupole time‐of‐flight‐tandem mass spectrometry

Contact Info

Product

Resources

About